Merck & Company (MRK) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.13
- Estimate
- -$0.26
- Surprise
- +49.4%
- Score at report (before → after)
- 5.9 → 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Merck & Company (MRK) reported a narrower loss than forecast — diluted EPS of -$0.13 against the -$0.26 estimate (a 49.4% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Buy (Wait) (5.9/10) to Sell at 5.7/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MRK Hold at 5.0/10.
4 of the last 4 quarters beat the estimate; this quarter's +49.4% surprise compares with a +18.5% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- Leverage penalty (D/E 1.3): -0.5
- Weak overall score: 5.0/10
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $144.01
- Price target
- $153.78
- Stop
- $136.87
- Upside to target
- +6.8%
The stock trades at 115.1× trailing but 15.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
MRK at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $355.10B
- P/E (fwd)
- 15.1
- P/E (ttm)
- 115.1
- 52-week range
- $77.58–$156.92
- Off 52-week high
- 8.2%
- RSI (14)
- 35
- Volume vs avg
- 0.78×
- Score today
- 5.0/10